Literature DB >> 9400007

The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents.

C Sánchez1, J Arnt, B Costall, M E Kelly, E Meier, R J Naylor, J Perregaard.   

Abstract

The anxiolytic potential of the selective sigma2 ligand 1-[4-[1-(4-Fluorophenyl)-1H-indol-3-yl]-1-butyl]spiro[isobenzofuran-1(3H),4-piperidine] [corrected] (Lu 28-179) was assessed in various animal models of anxiety in rodents. Lu 28-179 facilitated the exploratory behavior of mice and rats in the black and white two-compartment box over a large dose range. In the rat, the minimal effective dose (MED) was 0.18 nmol/kg (0.1 microg/kg), and in the mouse, the MED was 0.00018 nmol/kg (0.1 ng/kg). The anxiolytic-like effect was maintained after treatment with 1 microg/kg/day for up to 14 days, and no anxiogenic-like effects were seen upon withdrawal from repeated treatment. Lu 28-179 increased the time that pairs of rats spent in active social interaction (unfamiliar high-light conditions), MED = 0.1 ng/kg. Daily treatment with Lu 28-179 (1.8 nmol/kg = 1 microg/kg/day) for up to 4 weeks increased the social interaction time significantly compared with controls, and no anxiogenic-like effects were seen upon withdrawal. Furthermore, Lu 28-179 reversed shock-induced suppression of drinking in the rat (MED = 18,000 nmol/kg = 10 mg/kg). Lu 28-179 did not inhibit footshock-induced ultrasonic vocalization in the rat or isolation-induced aggressive behavior in the mouse. Lu 28-179 was over 100 times more potent than diazepam in the rat and mouse black and white test box and the rat social interaction test, whereas the potency of Lu 28-179 was comparable to that of lorazepam in reversal of shock-induced suppression of drinking. Lu 28-179 neither induced sedation nor impaired motor coordination, even at high doses (70,000 nmol/kg = 40 mg/kg). In conclusion, Lu 28-179 exerts potent and long-lasting anxiolytic-like effects in rodents without inducing sedation and withdrawal anxiogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400007

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

3.  Synthesis and pharmacological evaluation of indole-based sigma receptor ligands.

Authors:  Christophe Mésangeau; Emanuele Amata; Walid Alsharif; Michael J Seminerio; Matthew J Robson; Rae R Matsumoto; Jacques H Poupaert; Christopher R McCurdy
Journal:  Eur J Med Chem       Date:  2011-08-29       Impact factor: 6.514

Review 4.  The σ2 receptor: a novel protein for the imaging and treatment of cancer.

Authors:  Robert H Mach; Chenbo Zeng; William G Hawkins
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

5.  Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.

Authors:  Stine S Jensen; Stine A Petterson; Bo Halle; Charlotte Aaberg-Jessen; Bjarne W Kristensen
Journal:  BMC Cancer       Date:  2017-03-07       Impact factor: 4.430

6.  S2RSLDB: a comprehensive manually curated, internet-accessible database of the sigma-2 receptor selective ligands.

Authors:  Giovanni Nastasi; Carla Miceli; Valeria Pittalà; Maria N Modica; Orazio Prezzavento; Giuseppe Romeo; Antonio Rescifina; Agostino Marrazzo; Emanuele Amata
Journal:  J Cheminform       Date:  2017-01-21       Impact factor: 5.514

7.  The Sigma-2 Receptor Selective Agonist Siramesine (Lu 28-179) Decreases Cocaine-Reinforced Pavlovian Learning and Alters Glutamatergic and Dopaminergic Input to the Striatum.

Authors:  Anna M Klawonn; Anna Nilsson; Carl F Rådberg; Sarah H Lindström; Mia Ericson; Björn Granseth; David Engblom; Michael Fritz
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.